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Tuberous sclerosis (TSC) is an autosomal dominant
disorder characterized by a broad phenotypic spectrum
that includes seizures, mental retardation, renal dys-
function and dermatological abnormalities. Mutations
to either the TSC1 or TSC2 gene are responsible for the
disease. The TSC1 gene encodes hamartin, a 130-kDa
protein without significant homology to other known
mammalian proteins. Analysis of the amino acid se-
quence of tuberin, the 200-kDa product of the TSC2
gene, identified a region with limited homology to GTP-
ase-activating proteins. Previously, we demonstrated
direct binding between tuberin and hamartin. Here we
investigate this interaction in more detail. We show that
the complex is predominantly cytosolic and may contain
additional, as yet uncharacterized components along-
side tuberin and hamartin. Furthermore, because oli-
gomerization of the hamartin carboxyl-terminal coiled
coil domain was inhibited by the presence of tuberin, we
propose that tuberin acts as a chaperone, preventing
hamartin self-aggregation.
Tuberous sclerosis (TSC)1 is characterized by the develop-
ment of hamartomatous growths in many tissues and organs
(1). In particular, the brain and skin are affected, leading to the
classic phenotype of seizures, mental retardation, and facial
and ungual angiofibromas. Renal, cardiac, and retinal tissues
are also often affected. The majority of cases of TSC are spo-
radic, caused by a de novo mutational event. However, in fa-
milial cases the disease segregates as an autosomal dominant
trait, linked either to chromosome 9q34 (TSC1) or to chromo-
some 16p13.3 (TSC2). The genes mapping to these loci and
mutated in familial as well as sporadic cases of TSC have been
identified (2, 3). Screening large numbers of TSC patients
indicates that the majority of patients carry TSC2 mutations.
The ratio of TSC1 to TSC2 mutations in familial cases is
approximately equal (4).
The TSC1 gene codes for hamartin, a novel 130-kDa protein.
Hamartin has a relatively high proportion of hydrophilic amino
acids and a large region close to the carboxyl terminus that is
predicted to form coiled coil structures (amino acids 719–998).
Coiled coils mediate many protein-protein interactions (5). In
addition, hamartin contains a putative transmembrane do-
main, and it has been suggested that hamartin is associated
with membranes (6). The TSC2 gene encodes tuberin, a 200-
kDa protein that contains a stretch of 163 amino acids with
homology to the rap1 GTPase-activating proteins rap1GAP (3),
p130spa-1 (7), and Drosophila rapGAP1 (8). Tuberin has been
shown to have GAP activity toward rap1 (9) and rab5 (10),
another small GTPase of the Ras superfamily. Despite the
reported GAP activity, the exact function of tuberin is not yet
clear. Possible roles in endocytosis (10), cell cycle regulation
(11), differentiation (12), and steroid receptor modulated tran-
scription (13) have all been proposed.
Tuberin and hamartin form a complex in vivo (6, 14). Studies
using the yeast two-hybrid system indicate that the first of the
tuberin coiled coil regions (amino acids 346–371) and the first
heptad repeats of the hamartin coiled coil domain are involved
in the association between the two proteins (14). The demon-
stration that tuberin and hamartin bind directly and the fact
that mutations to either gene lead to the same phenotypic
spectrum suggest that both proteins are required for the cor-
rect function of the tuberin-hamartin complex, and that it is
the inactivation of the complex that leads to TSC. Here we
investigate the formation, composition, and subcellular local-
ization of the tuberin-hamartin complex and demonstrate that
tuberin may act as a chaperone, preventing self aggregation of
hamartin via its carboxyl-terminal coiled coil domain.
EXPERIMENTAL PROCEDURES
Generation of Constructs and Antisera—The full-length TSC1 and
TSC2 expression constructs have been described previously (14), al-
though in this study an untagged TSC2 expression construct (in
pcDNA3.1) was also used. Truncated TSC1 and TSC2 expression con-
structs were derived by appropriate restriction digestion of the full-
length cDNAs. Truncated TSC2 cDNAs encoding amino acids 1–1240,
1–1099, 1–607, and 1–252 plus 1536–1784, 1125–1784, and 607–1099
were cloned behind an amino-terminal polyhistidine epitope tag in a
pSG5-derived expression vector. Partial TSC1 cDNAs encoding amino
acids 228–572, 466–788, and 788–1153 were cloned into pcDNA3.1-
derived expression vectors containing either an amino-terminal Xpress
epitope tag or a carboxyl-terminal myc epitope tag (Invitrogen). The
rabaptin cDNA was isolated in a yeast two-hybrid screen with rab4 as
bait and cloned into pcDNA3.1His.2 Antisera specific for human tuberin
and hamartin have been described (14); antibodies against Xpress, myc
(Invitrogen), and polyhistidine (Qiagen) epitope tags were purchased
from the manufacturers. Acid a-glucosidase expression constructs and
antibodies have been described previously (21). Transferrin-Texas Red
conjugate was purchased from Molecular Probes (Leiden, The
Netherlands).
Transfections and Immunocytochemistry—Expression constructs
were transfected into COS-7 cells with LipofectAMINE and PLUS rea-
* This research was supported by grants from Noortman b.v., (Maas-
tricht, The Netherlands), the Dutch Epilepsiefonds, the Nederlands
Organisatie voor Wetenschappelijk Onderzoek, and the Dutch Cancer
Society. The costs of publication of this article were defrayed in part by
the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734
solely to indicate this fact.
‡ Present address: Birdshall Research Bldg., Mayo Clinic, Jackson-
ville, FL 32224.
§ To whom correspondence should be addressed: Dept. of Clinical
Genetics, Erasmus University, P. O. Box 1738, 3000 DR Rotterdam,
The Netherlands. Tel.: 31-10-4087197; Fax: 31-10-4089489; E-mail:
halley@kgen.fgg.eur.nl.
1 The abbreviations used are: TSC, tuberous sclerosis; PBS, phos-
phate-buffered saline. 2 B. Nagelkerken and P. van der Sluijs, submitted for publication.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 274, No. 50, Issue of December 10, pp. 35647–35652, 1999
© 1999 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org 35647
 at Erasm
us M
C M
edical Library on Decem
ber 4, 2006 
w
w
w
.jbc.org
D
ow
nloaded from
 
gent, as recommended by the manufacturer (Life Technologies). For
immunocytochemistry, cells on coverslips were fixed with 3% paraform-
aldehyde for 10 min at room temperature and permeabilized in either
0.1% Triton X-100 for 5 min or methanol for 20 min. The coverslips were
incubated with primary antibodies diluted 1:100 in phosphate-buffered
saline (PBS) containing 0.5% bovine serum albumin and 0.15% glycine,
followed by fluorescein isothiocyanate- or rhodamine isothiocyanate-
coupled secondary antibodies. Images were captured using the Power
Gene fluorescence in situ hybridization system on a Leica DM RXA
microscope. Images were processed using a filter wheel (Chroma Tech-
nology) and the Adobe Photoshop software package.
Yeast Two-hybrid Constructs and Assays—GAL4 activation and
binding domain constructs encoding amino acids 334–1153 of hamartin
(EE1a and EE1b, respectively) were as described previously (14). Yeast
host strain Y190 was cotransformed with 2.5 mg of each plasmid ac-
cording to the method of Klebe and co-workers (23). Transformants
were plated on media lacking tryptophan and leucine and on media
lacking histidine, tryptophan, and leucine. Colonies were tested for
b-galactosidase activity by a filter assay.
Subcellular Fractionation—HeLa cells (three confluent 10-cm plates)
were washed with PBS and collected by scraping into PBS. The cells
were pelleted by centrifugation at 2500 rpm for 5 min at 4 °C and
resuspended in homogenisation buffer (3 mM imidazole, pH 7.0, 250 mM
sucrose, 0.5 mM EDTA containing protease inhibitors (Complete; Roche
Molecular Biochemicals)). The cell suspension was homogenized by
repeated (10 times) passage through a 25-gauge hypodermic needle and
respun as above to remove the nuclei and unbroken cells. The post-
nuclear supernatant was then spun at 38,000 rpm for 60 min in a
Beckman ultracentrifuge SW50.1 rotor at 4 °C. The supernatant was
recovered, and the pellet was resuspended in homogenization buffer alone
or homogenization buffer containing one of the following: 10 mM Na2CO3,
pH 10.7, 1% Triton X-100, 1% 3-[(3-cholamidopropyl)dimethylammonio]-
1-propanesulfonic acid, 1% Triton X-100 plus 0.15 M NaCl, or 0.5 M NaCl.
The suspension was then respun at 38,000 rpm for 60 min in a Beckman
SW50.1 ultracentrifuge rotor at 4 °C, and the pellet and supernatant
fractions were recovered and analyzed by immunoblotting.
Flotation Gradient Centrifugation—A postnuclear supernatant was
prepared from three confluent 10-cm plates of HeLa cells as described
under “Subcellular Fractionation.” The postnuclear supernatant was
brought to 50% (w/w) sucrose and overlaid with a 15–40% (w/w) sucrose
gradient. After centrifugation at 42,000 rpm for 14 h in a Beckman
SW50.1 ultracentrifuge rotor at 4 °C, 0.2-ml gradient fractions were
analyzed for the presence of hamartin and tuberin by immunoblotting.
Sucrose Velocity Gradient Centrifugation—HeLa (confluent 10-cm
plate) or transfected COS (6-cm plate) cells were washed with PBS,
collected by scraping, and pelleted by centrifugation at 2500 rpm for 5
min at 4 °C. The cells were lysed in 250 ml of TEN buffer (50 mM
Tris-HCl, pH 8.0, 0.5 mM EDTA, 150 mM NaCl, 0.2% Nonidet P-40)
containing protease inhibitors (Complete; Roche Molecular Biochemi-
cals). After centrifugation at 10,000 rpm for 10 min at 4 °C, the cleared
detergent extract was layered on top of a 5–25% (w/w) sucrose gradient
in TEN buffer (3.5 ml) over a 0.5-ml 40% (w/w) sucrose cushion and
spun at 42,000 rpm for 14 h in an SW50.1 rotor at 4 °C. Fractions (0.2
ml) were collected from the top and analyzed by immunoblotting with
antibodies against hamartin and tuberin.
Gel Filtration—Postnuclear supernatants were prepared from HeLa
cells lysed in TEN buffer as described above. Gel filtration was then
performed on a Superose 6 column using the SMART fast protein liquid
chromatography system, according to the manufacturer’s guidelines
(Amersham Pharmacia Biotech), and 50-ml fractions were collected and
analyzed by immunoblotting. Thyroglobulin (660 kDa), catalase (240
kDa), bovine serum albumin (67 kDa), and chymotrypsinogen A (25
kDa) were run as protein molecular size markers.
Pulse-Chase Labeling Experiments—Twenty-four hours after trans-
fection, COS cells (T25 culture flask) were washed twice with 5 ml of
PBS and incubated at 37 °C for 30 min in 1 ml of serum-free medium
lacking methionine and cysteine (labeling medium). This medium was
then replaced with 0.5 ml of labeling medium containing 0.4 mCi/ml
Tran35S label (ICN). After pulse labeling by incubation for 10 min at
37 °C, the cells were washed extensively and chased in Dulbecco’s
modified Eagle’s medium containing 5% fetal calf serum for 0, 10, 30,
60, 120, and 180 min. The cells were then transferred to ice, washed
twice with 5 ml of PBS, and lysed in TEN buffer containing protease
inhibitors (Complete; Roche Molecular Biochemicals). The cell lysates
were cleared by centrifugation at 10,000 rpm for 10 min at 4 °C. The
cleared detergent lysates were transferred to 3 ml of antiserum, incu-
bated on ice for 60 min, and transferred to 35 ml of a 50% protein
A-Sepharose bead suspension. The beads were rotated gently at 4 °C for
60 min, washed extensively with TEN buffer and high salt buffer (50
mM Tris-HCl, pH 8.0, 0.5 mM EDTA, 500 mM NaCl, 1% Nonidet P-40),
and resuspended in Laemmli gel-loading buffer (24). The immunopre-
cipitates were separated according to standard procedures on 8% dena-
turing polyacrylamide gels. The gels were fixed, dried, and exposed to
x-ray film.
RESULTS
Tuberin and Hamartin Cofractionate—We first analyzed the
localization of tuberin and hamartin by subcellular fraction-
ation. HeLa cells were homogenized and fractionated by high
speed centrifugation into pellet and supernatant fractions. As
shown in Fig. 1, immunoblot analysis demonstrated that both
tuberin and hamartin were present exclusively in the pellet
fraction. Extraction of the pellet with either 3-[(3-cholamido-
propyl)dimethylammonio]-1-propanesulfonic acid or Triton
X-100 did not alter the fractionation profile of either protein.
After high-speed centrifugation, both tuberin and hamartin
were recovered in the pellet fraction. In contrast, resuspension
of the pellet in either high ionic strength (0.5 M NaCl) or high
pH (10 mM Na2CO3, pH 10.7) buffers resulted in partial solu-
bilization of both proteins. Cofractionation of tuberin and
hamartin is consistent with the two proteins binding together
in a complex, whereas solubilization by 10 mM Na2CO3 but not
by 1%Triton X-100 suggests that the complex is unlikely to be
associated with membranes and therefore that tuberin and
hamartin are more likely to be cytosolic proteins. Coimmuno-
precipitation of tuberin and hamartin from the high salt- and
high pH-solubilized fractions with antisera specific for either
protein indicated that, under these conditions, tuberin and
hamartin remained bound together in a complex (data not
shown).
Tuberin and Hamartin Are Localized Predominantly to the
Cytosol—To investigate the putative cytosolic localization of
tuberin and hamartin in more detail, flotation gradient density
centrifugation was performed. The postnuclear supernatant
from a HeLa cell homogenate was brought to a concentration of
50% sucrose and overlaid with a 15–40% sucrose gradient of
decreasing density. After high speed centrifugation at 42,000
rpm for 14 h in a Beckman SW50.1 rotor, fractions were col-
lected from the top of the gradient and analyzed by immuno-
blotting. Organelles and membranes disperse along the gradi-
ent according to their buoyant density, whereas cytosolic
proteins remain in the bottom layer. As shown in Fig. 2, the
vast majority of tuberin and hamartin remained in the lower
cytosolic fractions, whereas the lysosomal enzyme a-glucosi-
dase was present in the upper half of the gradient (data not
shown). This result strongly suggested that tuberin and
hamartin colocalise to the cytosol.
FIG. 1. Subcellular localization of the tuberin-hamartin com-
plex. The postnuclear supernatants from HeLa cell homogenates were
fractionated by high speed centrifugation as described under “Experi-
mental Procedures.” The pellet was extracted with salt or detergent and
recentrifuged. The first supernatant fraction (S1) and final pellet (P2)
and supernatant (S2) fractions were analyzed for the presence of tu-
berin and hamartin by immunoblotting.
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A very small proportion (,1%) of both tuberin and hamartin
consistently cofractionated with a membrane fraction. This
suggests that the tuberin-hamartin complex might associate
transiently with a specific membrane. Whether the tuberin-
hamartin complex shuttles between membrane-bound and cy-
tosolic states and the possible significance of this function of
the complex are currently under investigation.
Localization of Tuberin and Hamartin by Immunofluores-
cence Microscopy—Because our antibodies against tuberin and
hamartin did not enable us to define reliably the localization of
the endogenous proteins by immunocytochemistry, we ex-
pressed tuberin and hamartin exogenously, in transfected COS
cells. First we transfected a TSC2 expression construct. Tu-
berin was distributed diffusely in the cytoplasm and was not
obviously associated with intracellular membranes. Because
tuberin had been reported to be associated with the Golgi
complex (15), we used wheat germ agglutinin as a marker for
the Golgi complex. As shown in Fig. 3, we did not detect any
association between tuberin and the Golgi complex. Our results
are therefore not in agreement with those of Wienecke and
co-workers (15) but are consistent with the finding that tuberin
binds rabaptin, a cytosolic effector of rab5 (10, 16). We per-
formed double label immunofluorescence and coimmunopre-
cipitation studies on cells cotransfected with both TSC2 and
rabaptin cDNAs. As shown in Fig. 4, both proteins gave a very
similar diffuse, cytoplasmic labeling pattern. However, despite
this colocalization and in contrast to the findings of Xiao and
co-workers (10), we could find no evidence for a direct associa-
tion between tuberin and rabaptin in coimmunoprecipitation
experiments. Yeast two-hybrid assays for interaction between
tuberin and rabaptin were also negative (data not shown).
Next we investigated the expression of hamartin in trans-
fected COS cells. In contrast to the diffuse labeling of tuberin,
hamartin was predominantly localized to distinct, punctate
cytoplasmic structures. Furthermore, unlike tuberin, which is
partially recruited to the hamartin structures (14), we could
find no association between rabaptin and hamartin either by
double label immunofluorescence, as shown in Fig. 4, or by
coimmunoprecipitation (data not shown). Additional transfec-
tion experiments to express a series of truncated hamartin
variants indicated that amino acids 788–1153, containing a
large proportion of the predicted coiled coil domain, caused the
punctate labeling. Hamartin constructs lacking this domain
did not result in the same distinctive labeling pattern (data not
shown). These results suggested that the predicted coiled coil
domain was required either for association of hamartin with a
membrane-bound organelle or alternatively for the formation
of large, hamartin-containing protein aggregates.
To investigate the subcellular localization of hamartin in
more detail, we performed a series of double label immunoflu-
orescence experiments with marker proteins for the central
vacuolar system. One possibility was that the punctate labeling
reflected association with a membrane bound organelle. How-
ever, hamartin did not co-localize with the endoplasmic retic-
ulum marker protein disulphide isomerase, with the Golgi com-
plex-specific lectin wheat germ agglutinin, with the early
endosomal and late endosomal markers rab5 and rab7, or with
lysosomal acid a-glucosidase (data not shown). Moreover, the
structures did not label with fluorescently labeled transferrin,
a marker for early endocytic compartments. To investigate the
alternative explanation that the punctate structures were at-
tributable to specific self-aggregation of hamartin caused by
homomeric interaction of the carboxyl-terminal coiled coil do-
main, yeast two-hybrid assays were performed. A cDNA encod-
ing the hamartin coiled coil region (amino acids 334–1153) was
cloned into Gal4 activation (pGADGH) and binding (pGBT9)
domain constructs and tested for interaction using the b-galac-
tosidase assay. As shown in Fig. 5, a strong induction of b-ga-
lactosidase activity was detected, suggesting that the hamartin
coiled coil domains had the ability to form homodimers. No
b-galactosidase activity was detected with either activation or
FIG. 2. Flotation gradient centrifugation of tuberin and
hamartin. A HeLa cell homogenate was brought to 50% (w/w) sucrose
and overlaid with a 15–40% (w/w) sucrose gradient. After centrifuga-
tion at 42,000 rpm for 14 h at 4 °C in a Beckman SW50.1 rotor, 0.2-ml
fractions were analyzed by immunoblotting. Tuberin and hamartin are
indicated. The bar indicates increasing sucrose density.
FIG. 3. Localization of tuberin and wheat germ agglutinin in
COS cells. A, COS cells transfected with an a-glucosidase expression
construct, showing clear overlap between the expression of acid a-glu-
cosidase (green fluorescence) and the distribution of the Golgi complex,
as revealed by a wheat germ agglutinin-rhodamine conjugate (red flu-
orescence). Acid a-glucosidase is transported through the Golgi complex
en route to the lysosome. B, same image as in A, without the a-gluco-
sidase signal to indicate the Golgi-specific wheat germ agglutinin signal
(red fluorescence). C, COS cells transfected with TSC2. The distribution
of tuberin (green fluorescence) is clearly distinct from that of the Golgi
marker wheat-germ agglutinin (red fluorescence).
FIG. 4. Localization of tuberin, hamartin, and rabaptin in COS
cells. Double label immunofluorescence microscopy was performed on
co-transfected COS cells overexpressing hamartin and Xpress-tagged
rabaptin (A–C) and tuberin and Xpress-tagged rabaptin (D–F). A,
hamartin expression, showing the characteristic punctate labeling pat-
tern in the cytoplasm (green fluorescence). B, combined double label
image showing hamartin, as in A (green fluorescence) and rabaptin (red
fluorescence). Rabaptin shows the expected diffuse, cytoplasmic label-
ing pattern, and there is minimal overlap of the hamartin and rabaptin
signals. C, rabaptin expression (red fluorescence). D, tuberin expres-
sion, showing typical diffuse cytoplasmic staining (green fluorescence).
E, combined double label image showing tuberin, as in D (green fluo-
rescence), and rabaptin (red fluorescence). Yellow indicates significant
overlap of the tuberin and rabaptin signals. F, rabaptin expression (red
fluorescence).
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binding domain-hamartin fusion construct alone.
Hamartin and Tuberin Cofractionate by Velocity Gradient
Centrifugation—The fact that hamartin interacted with itself
in yeast two-hybrid assays suggested that the labeling pattern
observed in cells transfected with TSC1 might indeed represent
hamartin self-aggregation. We took a biochemical approach to
investigate this question. COS cells transfected with TSC1
cDNA were lysed in 0.2% Nonidet P-40, and the lysates were
cleared by centrifugation for 10 min at 10,000 rpm. The result-
ing supernatant was then overlaid onto a 5–25% sucrose gra-
dient and subjected to high speed centrifugation at 42,000 rpm
in a Beckman SW50.1 rotor for 14 h. As shown by the immu-
noblot analysis in Fig. 6a, hamartin was confined to the pellet
fraction and was not detectable in the gradient. This suggested
that hamartin was present in detergent-resistant protein com-
plexes that were unlikely to be associated with membranes,
because the latter were solubilized by the 0.2% Nonidet P-40 in
the lysis buffer. Identical results were obtained with detergent
lysates prepared from COS cells expressing a truncated hamar-
tin protein containing amino acids 788–1153 only (data not
shown), whereas addition of 0.5 M NaCl to the lysate did not
affect the distribution of hamartin. Therefore, using three in-
dependent assays, we showed that the coiled coil domain of
hamartin promotes self-aggregation into insoluble, detergent-
and salt-resistant protein complexes.
As shown in Fig. 6b, using the same sucrose gradient cen-
trifugation procedure on detergent lysates of COS cells trans-
fected with TSC2, we detected .95% of tuberin approximately
halfway along the gradient. Only a minor proportion (,5%)
was detectable in the pellet fraction, suggesting that most if not
all of the overexpressed tuberin was not associated with the
dense, detergent-resistant fraction and was therefore, in con-
trast to hamartin, not part of an insoluble protein complex. The
different sedimentation profiles of tuberin and hamartin re-
flected the distinct immunofluorescent labeling patterns; over-
expressed tuberin produced a diffuse cytosolic labeling, in con-
trast to the punctate labeling of hamartin.
To gain more insight into the intracellular localization of the
tuberin-hamartin complex, high speed velocity gradient cen-
trifugation was performed on detergent lysates of nontrans-
fected HeLa cells. As shown in Fig. 6c, tuberin and hamartin
co-migrated through the gradient. Similar results were ob-
tained with COS cells cotransfected with TSC1 and TSC2 (data
not shown). Neither protein was present in the pellet fraction,
suggesting that tuberin and hamartin form a soluble complex,
and that tuberin may therefore prevent the formation of large,
insoluble hamartin aggregates, possibly by interfering with
hamartin-hamartin binding.
The Tuberin-Hamartin Complex Forms Rapidly after Trans-
lation—Because tuberin binding prevented the formation of
large, detergent-insoluble hamartin aggregates, we reasoned
that tuberin may act as a chaperone, maintaining hamartin in
a soluble form in the cytosol by preventing hamartin from
binding to itself. According to this idea, the association between
tuberin and hamartin would be expected to occur rapidly after
hamartin is synthesized. To investigate this issue we trans-
fected COS cells with TSC1 and TSC2 cDNAs and metaboli-
cally labeled the proteins for 10 min with [35S]methionine and
[35S]cysteine (TranS). The cells were subsequently chased in
media lacking labeled amino acids for between 0 and 180 min.
The cells were then lysed, tuberin and hamartin were immu-
noprecipitated from the cleared lysates, and coimmunoprecipi-
tating proteins were resolved by SDS-polyacrylamide gel elec-
trophoresis. As shown in Fig. 7, even at the earliest chase times
tuberin and hamartin coimmunoprecipitated. Because protein
synthesis occurs at a rate of ;5–10 amino acids per second (17),
it takes ;5 min to synthesize full-length tuberin (1784 amino
acids) and hamartin (1164 amino acids); therefore, the two
proteins must associate during or very soon after synthesis.
Gel Filtration Analysis Indicates That the Molecular Size of
the Tuberin-Hamartin Complex is .450 kDa—To determine
the size of the tuberin-hamartin complex, we performed gel
filtration on HeLa cell detergent lysates. Samples were loaded
on a Superose 6 column, and fractions eluting from the column
were analyzed by immunoblot. As shown in Fig. 8, tuberin and
hamartin co-eluted in fractions 14–18, between the thyroglob-
ulin (660 kDa; fraction 12) and catalase (240 kDa; fraction 22)
molecular size markers. The elution positions of the marker
proteins are indicated with arrowheads. Co-elution of tuberin
and hamartin helps confirm that both proteins are in a complex
and provides a first indication of the size of this complex. We
FIG. 5. Yeast two-hybrid analysis of homomeric binding of the
hamartin coiled coil domain. Amino acids 334–1153 of hamartin
fused to to the GAL4 DNA-binding and trans-activation domains (GBT-
EE1b and GAD-EE1a, respectively) were tested for interaction by col-
ony growth on selective medium. a, GBT-EE1b and GAD control co-
transformation; no growth on -leu -trp -his plates. b, GBT-TSC2 and
GAD control cotransformation; no growth on -leu -trp -his plates. c, GBT
and GAD-EE1a control cotransformation; no growth on -leu -trp -his
plates. d, GBT-EE1b and GAD-EE1a test cotransformation; growth on
-leu -trp -his plates indicates homomeric binding between the hamartin
activation and binding domain constructs. e, GBT-TSC2 and GAD-
EE1a positive control co-transformation; growth on -leu -trp -his plates
confirms the interaction between tuberin and hamartin described
previously (14).
FIG. 6. Velocity gradient centrifugation of tuberin and hamar-
tin. High speed centrifugation through sucrose gradients was per-
formed on lysates prepared from COS cells overexpressing hamartin (a)
and tuberin (b). Tuberin and hamartin were detected by immunoblot-
ting. (c), Lysates prepared from nontransfected HeLa cells were ana-
lyzed according to the same protocol. The bar indicates the direction of
the gradient.
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estimate that the molecular size of the tuberin-hamartin com-
plex is .450 kDa. The molecular sizes of tuberin and hamartin
are 200 and 130 kDa, respectively. Therefore, co-elution of the
two proteins is consistent with the presence of a ;330-kDa
tuberin-hamartin dimer but not a 2:2 tuberin-hamartin tet-
ramer, which would be expected to elute in fraction 12, together
with the 660-kDa thyroglobulin marker. Because we estimate
that the molecular size of the complex is .450 kDa, it seems
likely that the tuberin-hamartin complex contains additional,
as yet unidentified, protein components. The resolution of the
Superose 6 column was not sufficient to exclude 2:1 or 1:2
tuberin-hamartin heterotrimers (;530 and ;460 kDa,
respectively).
DISCUSSION
Current evidence indicates that many of the lesions charac-
teristic of TSC arise when a second somatic mutation abolishes
completely the expression of either hamartin or tuberin (18).
Because the two proteins bind each other, and because inacti-
vation of either gene causes the same disease, it follows that
the tuberin-hamartin complex is required for whatever func-
tion is disrupted in TSC. Furthermore, it implies that the two
proteins should co-localize to the same intracellular compart-
ment(s). Our data, from a variety of different biochemical ap-
proaches, indicate that this is indeed the case, and that the
majority of the tuberin-hamartin complex is cytosolic. How-
ever, we also obtained evidence that at steady state a very
small proportion is associated with membranes. Although the
significance of this finding still has to be confirmed, it does not
rule out a role for the tuberin-hamartin complex in vesicle
docking (6).
We (14) and others (6) have shown that tuberin and hamar-
tin form a complex, and it is difficult to reconcile the differing
localizations of tuberin and hamartin reported in the literature
with these findings, as well as with the co-fractionation results
detailed here. We could not confirm the reported punctate
distribution of hamartin in cells expressing endogenous levels
of the protein (6). Furthermore, in line with others (10), we
could not support the proposed localization of tuberin to the
Golgi (15). One possible explanation is that the formation and
localization of the tuberin-hamartin complex is different in
different cell types, because Planck and co-workers (6) studied
human kidney 293 cells, and Wienecke and co-workers (15)
investigated the localization of tuberin in different renal tu-
mor, adenocarcinoma, and astrocytoma cell lines, whereas
most of our studies were performed in HeLa cells.
The tuberin-hamartin complex is large (we estimate that the
molecular size is .450 kDa), and binding between the two
proteins is resistant to detergent extraction, high salt, and high
pH. Resistance to detergent indicates that membrane associa-
tion is not required for formation of the complex, consistent
with earlier yeast two-hybrid assays (14), whereas solubility of
the complex in a high pH sodium carbonate buffer indicates
that the tuberin-hamartin complex is not an integral mem-
brane complex. Partial solubilization in high salt is consistent
with association between the tuberin-hamartin complex and
additional cellular components. However, we could find no
evidence that rabaptin was associated with tuberin, hamartin,
or the tuberin-hamartin complex, suggesting that further
searches for proteins that interact with either tuberin or
hamartin are necessary to unravel the function of the tuberin-
hamartin complex.
Hamartin can form homomeric protein complexes. Whether
this interaction is important with respect to the formation of
the tuberin-hamartin complex or for the pathogenesis of TSC is
not yet clear. Our results suggest that the punctate labeling
pattern observed in cells overexpressing hamartin is attribut-
able to oligomerization of the coiled coil domain and that tu-
berin may interfere with this process, because the gel filtration
and ultracentrifugation fractionation profiles of hamartin in
the presence of tuberin are different from those in the absence
of tuberin. Therefore, tuberin may act as a chaperone for
hamartin. Demonstration that the tuberin-hamartin complex
forms during or very soon after protein synthesis provides
support for this idea.
We could find no evidence for hamartin-hamartin aggrega-
tion in cells expressing normal levels of hamartin (and tu-
berin), and the punctate labeling and fractionation profile may
therefore be caused by overexpression. However, it will be
interesting to study the fractionation of hamartin from cells in
which tuberin expression has been lost, in Eker rat-derived
tumor cell lines for example. Analogous to the disruption
caused by the aggregation of insoluble proteins containing long
glutamine stretches (19), aggregation of hamartin may also
interfere with normal neuronal cell function.
Considering the consequences of TSC2 or TSC1 inactivation,
the data presented here suggest that the formation and local-
ization of the complex is critically dependent on the direct
interaction between tuberin and hamartin. Because loss of
either protein leads to TSC, and because the activity of tuberin
may be altered when associated with hamartin, the important
function with respect to the pathogenesis of the disease may be
that of the hamartin-containing complex. Reports on the puta-
tive functions of tuberin have generally focused on tuberin
alone and have not taken hamartin into account (9–13, 20).
This may partly explain the diverse range of proposed func-
tions and suggests that the true function of the tuberin-hamar-
tin complex, with particular regard to the pathogenesis of TSC,
has yet to be established.
FIG. 7. Pulse-chase coimmunoprecipitation of metabolically
labeled tuberin and hamartin. COS cells cotransfected with TSC1
and TSC2 were pulse-labeled for 10 min and then chased for different
periods as described under “Experimental Procedures.” After each
chase, hamartin was imunoprecipitated (IP) from the cleared cell ly-
sate. Co-immunoprecipitated tuberin was detected at each time point.
Similarly, hamartin was co-immunoprecipitated when tuberin was
immunoprecipitated.
FIG. 8. Gel filtration analysis of the tuberin-hamartin com-
plex. A HeLa cell lysate was separated on a Superose 6 gel filtration
column according to the manufacturer’s recommendations. Fractions
were collected, and tuberin and hamartin expression in each fraction
was monitored by immunoblotting. Molecular size marker proteins
were run on the same column under identical buffer conditions. The
positions of thyroglobulin (660 kDa; fraction 12), catalase (240 kDa;
fraction 21), bovine serum albumin (67 kDa; fraction 29) and chymot-
rypsinogen A (25 kDa; fraction 33) are indicated (arrowheads). Endog-
enous tuberin and hamartin both eluted in the early, high molecular
size fractions (peak fraction 16; estimated molecular size, .450 kDa).
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In summary, we have shown that tuberin and hamartin
colocalize, and that the tuberin-hamartin complex is cytosolic
and may contain additional components. In addition, our re-
sults indicate that both tuberin and hamartin are required for
the correct localization and function of the complex. Binding
between tuberin and hamartin occurs rapidly after synthesis of
the two proteins and prevents hamartin self-aggregation
caused by intermolecular homomeric binding of the coiled coil
domain. We are continuing with a more detailed analysis of the
tuberin-hamartin complex, its localization, function, and addi-
tional component parts.
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